3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
91
Neoplasm Metastasis
24
Neoplasms
14
Brain Neoplasms
13
Prostatic Neoplasms
10
Endometrial Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Ovarian Neoplasms
7
Glioblastoma
7
Glioma
6
Triple Negative Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Colorectal Neoplasms
5
Sarcoma
4
Recurrence
4
Pancreatic Neoplasms
4
Lymphoma, Non-Hodgkin
4
Sarcoma, Ewing
3
Osteosarcoma
3
Neoplasms by Site
3
Multiple Myeloma
3
Meningioma
3
Melanoma
3
Liposarcoma
3
Carcinoma, Renal Cell
3
Breast Diseases
3
Unilateral Breast Neoplasms
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Interventions
Temozolomide
3
XENP 1595
2
Trastuzumab
2
Sodium Chloride
2
Dexmedetomidine
2
Cancer Vaccines
2
Adjuvants, Immunologic
2
veliparib
1
tucatinib
1
tipifarnib
1
sagopilone
1
pembrolizumab
1
interferon gamma-1b
1
glutathione pegylated liposomal doxorubicin
1
elacestrant
1
abemaciclib
1
Saline Solution
1
Rituximab
1
Radiotherapy
1
Radiation
1
RAD1901
1
Oncolytic Virotherapy
1
Interferon-gamma
1
Immunotherapy
1
Dasatinib
1
Craniotomy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Central Nervous System Diseases
×
abemaciclib
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled